DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 019872/S-040

SUPPLEMENT APPROVAL

McNeil Consumer Healthcare
Attention: Eileen Harman
Associate Director, Regulatory Affairs
7050 Camp Hill Road
Fort Washington, PA 19034

Dear Ms. Harman:

Please refer to your Supplemental New Drug Application (sNDA) dated September 6, 2013, received September 6, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tylenol 8 HR Arthritis Pain (acetaminophen 650 mg) Extended-Release Tablet.

We acknowledge receipt of your amendments dated November 22, 2013 and February 25, 2014.

This "Changes Being Effected" supplemental new drug application proposes to incorporate the new allergy alert warning on the label to comply with FDA's correspondence, dated August 1, 2013.

We have completed our review of this application. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

LABELING

Submit final printed labeling, as soon as they are available, but no more than 30 days after they are printed. The final printed labeling (FPL) must be identical to the labels submitted February 25, 2014, and must be in the "Drug Facts" format (21 CFR 201.66), where applicable. These labels are listed below:

Tylenol 8 HR Arthritis Pain labels

- 2-count professional sample pouch
- 100-count immediate container label (no outer carton)
- 24-, 225- and 290-count immediate container and outer carton

Tylenol 8 HR labels

- 2-count pouch
- 100-count immediate container label (no outer carton)
- 24- and 225-count immediate container and outer carton

We remind you that S-039 was submitted before FDA sent the advice letter to include the allergy alert on all acetaminophen products. S-040 is considered the approved labeling for your Tylenol 8 HR Arthritis Pain and Tylenol 8 HR products. However, in your cover letter to S-040, you noted that (b) (4) As S-039 was approved without the allergy alert, we remind you to submit a prior approval supplement to update the labels in S-039 with the allergy alert and receive approval before marketing.

The final printed labeling should be submitted electronically according to the guidance for industry titled "Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)." Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission "**Final Printed Labeling for approved NDA 019872/S-040**." Approval of this submission by FDA is not required before the labeling is used.

DRUG REGISTRATION AND LISTING

All drug establishment registration and drug listing information is to be submitted to FDA electronically, via the FDA automated system for processing structured product labeling (SPL) files (eLIST). At the time that you submit your final printed labeling (FPL), the content of labeling (Drug Facts) should be submitted in SPL format as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf. In addition, representative container or carton labeling, whichever includes Drug Facts, (where differences exist only in the quantity of contents statement) should be submitted as a JPG file.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Jade Pham, Regulatory Project Manager at (301) 796-7031.

Sincerely,

{See appended electronic signature page}

Theresa Michele, M.D.
Director
Division of Nonprescription Clinical Evaluation
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

ENCLOSURES:
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

THERESA M MICHELE
03/06/2014